COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03751007
Recruitment Status : Active, not recruiting
First Posted : November 23, 2018
Last Update Posted : March 24, 2020
Intrexon Actobiotics NV, d/b/a Precigen Actobio
TFS Trial Form Support
Information provided by (Responsible Party):
Precigen Actobio T1D, LLC

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 31, 2020
Estimated Study Completion Date : May 30, 2021